Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. develops oligonucleotide therapies for severe neuromuscular and neurological diseases. The company’s Enhanced Delivery Oligonucleotide platform uses cell-penetrating peptides to improve tissue penetration, cellular uptake and nuclear delivery of conjugated oligonucleotide therapeutics.
Recurring PepGen news centers on clinical development of PGN-EDODM1 for myotonic dystrophy type 1, including FREEDOM and FREEDOM2 study updates, safety observations, splicing correction data, regulatory communications and trial geography. Coverage also includes financial results, cash runway commentary, intellectual-property developments such as composition-of-matter patent protection, executive and governance updates, and equity compensation actions under Nasdaq rules.
PepGen Inc. reported its Q2 2022 financial results, highlighting a successful IPO that raised $122.9 million, enabling operations through mid-2025. The company initiated its Phase 1 clinical trial for PGN-EDO51, targeting Duchenne muscular dystrophy. With $218.8 million in cash, PepGen plans to release initial clinical findings by year's end and expects to file for an Investigational New Drug (IND) application for PGN-EDODM1 in early 2023. R&D expenses rose to $14.2 million, reflecting increased clinical and personnel costs, leading to a net loss of $17.3 million for the quarter.
PepGen Inc. announced the appointment of Caroline Godfrey, Ph.D., to its Scientific Advisory Board, marking a transition from her role as Senior Vice President of Discovery. Dr. Godfrey, a scientific co-founder of the company, played a crucial role in its establishment and early-stage research. The move aims to leverage her expertise as PepGen expands its operations in Boston and focuses on advancing oligonucleotide therapies for neuromuscular and neurological diseases. CEO James McArthur expressed confidence in her continued contributions to the company's mission.
PepGen Inc. reported strong growth as a clinical-stage biotechnology company, focusing on treating severe neuromuscular diseases. Following a successful IPO in May, raising $122.9 million, the company began a Phase 1 trial of PGN-EDO51 for Duchenne muscular dystrophy (DMD) in April 2022. As of March 31, 2022, PepGen had $118.9 million in cash, expected to fund operations until mid-2025. However, net losses reached $18.2 million for Q1 2022, highlighting significant research and administrative expenses as the company ramps up development.
PepGen, a clinical-stage biotech firm, has priced its initial public offering (IPO) at $12.00 per share, aiming to raise $108 million through the sale of 9 million shares. An additional 1.35 million shares may be purchased by underwriters over a 30-day period. The shares will trade on the Nasdaq under the symbol 'PEPG' starting May 6, 2022, with the closing date set for May 10, 2022. BofA Securities, SVB Securities, and Stifel are managing the offering, which follows a registration statement that became effective on May 5, 2022.